1 Association between Cardiovascular Disease Risk and long COVID-19: A

2 Systematic Review and Meta-analysis

- 3 Yunxia Huang^{a, b}, Zhuofeng Wen^{a, b}, Hongbin Luo^{a, b}, Yijie Liao^{a, b}, Zisheng Chen^{a, *}
- ^aDepartment of Respiratory and Critical Care Medicine, the Sixth Affiliated Hospital
- 5 of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan 511518,

6 China;

⁷ ^bThe Sixth Clinical Medical School of Guangzhou Medical University;

- ⁸ Corresponding author: E-mail addresses: williamstdb@gzhmu.edu.cn.
- 9

10 ABSTRACT

Objectivate To assess demographic characteristics and investigate the correlation
 between cardiovascular diseases and long COVID-19 patients.

13

Methods Comprehensive details, encompassing the first author's name, publication year, sample inclusion criteria, sample size, and demographic characteristics, including age and gender of participants, were systematically extracted from all incorporated studies. Meanwhile, the analysis encompassed the assessment of the risk associated with nineteen cardiovascular outcomes.

19

20

21 **Results** A total of 3, 201 potentially eligible studies were initially identified for

²² consideration. Following rigorous literature screening and quality control measures, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

eighteen studies, encompassing 46, 083, 975 patients, met the specified criteria. In 23 comparison to the control cohort, our investigation unveiled a heightened risk of 19 24 25 cardiovascular outcomes associated with long COVID-19. Our meta-analysis revealed a pooled OR of 1.68 (95% CI 1.55-1.81) ($I^2 = 69.1\%$, p= 0.000) for the overall risk of 26 cardiovascular outcomes, indicating an elevated risk of cardiovascular diseases in 27 individuals affected by long COVID-19. While the heterogeneity was relatively high, 28 it is essential to acknowledge that all studies inherently carry an unavoidable risk of 29 bias, irrespective of their quality rating. Moreover, there appears to be no significant 30 31 publication bias based on the funnel plot, Begg's, and Egger's tests. Sensitivity analysis did not reveal substantial alterations in the overall stability of the results. 32

33

Conclusions Our meta-analysis substantiates that individuals afflicted with long COVID-19 face an elevated risk of developing cardiovascular diseases. Routine assessment of cardiac function is deemed essential for a long COVID-19 high-risk cardiovascular disease population. Timely interventions have the potential to mitigate the risk of cardiovascular diseases and associated mortality in this population.

39

40 TRIAL REGISTRATION PROSPERO Identifier: CRD42023455701

41

42 Keywords: Coronavirus disease 2019; Cardiovascular Disease; Long COVID-19.

43

44 Abbreviations: WHO, World Health Organization; HR, Hazard ratio; RR, risk ratio;

OR, odds ratio; CI, confidence interval; REM, random-effects model; ACE2,
angiotensin-converting enzyme 2; SARS-CoV-2, Severe Acute Respiratory
Syndrome Coronavirus 2 CoV; MESH, Medical Subject Headings; NOS,
Newcastle-Ottawa Scale; FEM, fixed-effect model; BMI, Body Mass Index; IL,
interleukin;

50

51 **1. Introduction**

Since the COVID-19 global pandemic, there have been over 771, 151, 224 cumulative 52 cases and 6, 960, 783 deaths of COVID-19 all over the world, as of 4 October 2023¹. 53 Recently, more and more researches have posited that COVID-19 may exert 54 deleterious effects on patients beyond the acute phase, including potential negative 55 impacts on respiratory, neurologic, mental, gastrointestinal, and cardiovascular 56 health²⁻⁵. Consequently, the terminology 'long COVID' or 'post-COVID-19 syndrome' 57 has emerged, specifically denoting the persistent clinical manifestations observed 58 beyond the acute phase⁶. This fluctuating condition can be classified into two stages, 59 namely post-acute and chronic, delineated by the duration of follow-up during which 60 the symptoms manifest⁷. In the view of some studies, approximately one-eighth of the 61 global population is projected to experience post-COVID-19 conditions. This implies 62 that, considering over 651 million documented COVID-19 cases worldwide and a 63 conservative estimate of a 10% incidence rate among infected individuals, around 65 64 million individuals worldwide may be affected by long COVID^{8,9}. During the 65 trajectory of long COVID-19, prevalent symptoms and signs include olfactory 66

dysfunction, dyspnea, gustatory dysfunction, cough, fatigue, myalgia, among others,
contributing to a diminished quality of life and decreased work efficiency¹⁰. Moreover,
COVID-19 is implicated in significant multiorgan dysfunction, encompassing
myocardial injury, acute respiratory distress syndrome, systemic shock, liver injury,
renal injury, etc^{11,12}.

72

Relevant studies suggest that the zinc metallopeptidase angiotensin-converting 73 enzyme 2 (ACE2), responsible for converting angiotensin II to angiotensin, serves as 74 the functional receptor for Severe Acute Respiratory Syndrome Coronavirus 2 CoV 75 (SARS-CoV-2), whose interaction is implicated in myocardial damage, representing 76 one potential mechanism, but the specific mechanisms remain elusive^{13,14}. As matters 77 78 stand, there is an increasing number of reports highlighting cardiovascular complications in long COVID, including arrhythmia, inflammatory heart disease, 79 heart failure and various other cardiac disorders^{15,16}. Actually, we have to 80 acknowledge the existing controversy still surrounding the relationship between 81 cardiovascular disease and long COVID-19. Specifically, regarding ischemic heart 82 disease, findings from Hannah R Whittaker et al² suggest a lower risk for long 83 COVID-19 patients, while studies by Kwan Hong et al¹⁷ and Yan Xie et al¹⁸ present 84 contrasting perspectives. Consequently, our current understanding of the association 85 between cardiovascular disease and long COVID-19 remains limited. Further 86 comprehensive evidence is imperative to establish a definitive association between 87 cardiovascular disease and patients with long COVID-19. 88

89

As a consequence, we analyzed and reviewed relevant cohort studies to sort out the
association of long COVID-19 patients with cardiovascular disease risk by the mean
of meta-analysis comprehensively and deeply.

93

94 2. Materials and methods

95 2. 1. Literature search

We performed a comprehensive meta-analysis of prospective and retrospective cohort 96 97 studies documenting at least one combination of risk factors and outcomes. Our search strategy encompassed multiple databases, such as Web of Science, Scopus, 98 99 Cochrane Library, Embase and PubMed, up to August 18, 2023, and was limited to 100 articles published solely in English. Our search used the keywords "long COVID-19", "cardiovascular disease" and their Medical Subject Headings (MeSH) terms. Studies 101 were required to fulfill the following medical standards: (1) only include 102 103 prospective/retrospective cohort studies and case-control studies; (2) Patients with long COVID-19 were studied; (3) Outcome indicators: the risk of cardiovascular 104 disease among patients with confirmed long COVID-19 (HR, RR and OR, with 95% 105 CI); (4) Written in English only. Studies were excluded if they lacked the provision of 106 OR/RR/HR with 95% CI, exhibited poor methodological quality, reported individual 107 cases, or lacked the specified indicators of accomplishment mentioned above. Our 108 109 research was registered in the Prospective Register of Systematic Reviews 110 (PROSPERO ID CRD42023455701).

111

112 2. 2. Data acquisition

Four investigators (Y. H., Z. W., H. L., Y. L.) independently extracted data and 113 resolved discrepancies through consensus by four reviewers. The results underwent 114 review by the senior investigator (Z. C.). When available, information on target 115 outcomes was documented using WPS software. General details, including the first 116 author's name, publication year, sample inclusion criteria, sample size, and 117 demographic data such as age and gender of study participants, were systematically 118 119 collected from all included studies. Incidence outcomes were compared between the COVID-19 and non-COVID-19 groups. 120

121

122 **2.3.** Quality assessment

The risk of bias in the included cohort studies was evaluated using the
Newcastle-Ottawa Scale (NOS). Studies achieving a score of at least 7 out of 10 were
classified as high-quality studies.

126

127 **2. 4. Statistical analyses in Meta-analysis**

We conducted meta-analyses using a statistical software package (Stata 11.0). Heterogeneity among the studies was assessed through χ^2 analysis. If the inconsistency values (I²) exceeded 50%, a REM was applied; otherwise, a fixed-effect model (FEM) was utilized. In the presence of heterogeneity, we explored its source through subgroup analysis and sensitivity analysis. The combined HR, RR, OR, with

its corresponding 95% CI was computed. Subsequently, funnel plots, Begg and Egger bias index tests, and meta-regression were employed to identify potential publication bias. All P values were two-sided, and statistical significance was set at P < 0.05.

136

137 **3. Results**

138 **3. 1. Search results and study characteristics**

The selection process is depicted in Figure. 1 via a flowchart. 3, 201 studies were 139 deemed potentially eligible across various databases. 591 duplicates were excluded, 140 141 then 2610 left. After extensively comparing the studies' relevant information, 1, 001 researchers were included, but 1,609 were excluded (150 case reports, 371 conference 142 abstracts, 197 comments, 20 editorials, 71 letters, 117 notes, 631 review, 52 143 144 meta-analyses). According to the studies for the title and abstract screening, 136 articles were taken into the next round, and 865 were dismissed (60 not related to 145 COVID-19, 270 irrelevant research, 513 about other diseases, 22 not cohort studies). 146 147 Finally, eighteen articles remained after reading the full articles, and 118 were ruled out (17 studies with incomplete outcomes, 88 irrelevant researches, 13 irrelevant 148 interventions). 149

150

The characteristics of the included studies are presented in Table. 1 Eighteen cohort studies, including 3 prospective cohort studies and 15 retrospective cohort studies, were conducted in developed and developing countries involving different races. The total number of patients included in these studies was 46, 083, 975 of which more

155	than 37, 475, 604 were in the no COVID-19 group, and over 8, 327, 779 were in the
156	COVID-19 group. The duration of the studies ranged from 5 to 39 months. The male
157	ranged from 41.2% to 90.42%, and the mean age of the participants ranged from
158	27.99 (\pm 7.96) to 73.85 (\pm 4.50) years. Only seven studies reported the mean Body
159	Mass Index (BMI) of the no COVID-19 group, which ranged from 26 (\pm 5.0) kg/m ² to
160	30.2 (\pm 5.7) kg/m ² , while the mean BMI of the COVID-19 group ranged from 27.1
161	(±6.7) kg/m ² to 31.00 (±6.06) kg/m ² . Furthermore, there were eight studies collected
162	the smoking history of the individuals: 5.52% to 57.43% in no COVID-19 group
163	while 4.41% to 59.69% in COVID-19 group. In addition, eleven researches provided
164	the prevalence of diabetes: 7.42% to 77.22% in no COVID-19 group while 8.34% to
165	75.61% in COVID-19 group. What's more, there were also five studies recorded the
166	prevalence of high cholesterol: 8.63% to 74.29% in no COVID-19 group while 8.80%
167	to 72.79% in COVID-19 group. Lastly, three articles mentioned the morbidity of
168	coronary heart disease: 22.12% to 78.21% in no COVID-19 group, then, 22.12% to
169	35.74% in COVID-19 group.

170

171 **3. 2. Quality assessment**

We used the NOS, a measure of bias, to analyze the case-control and cohort studies. Only studies at least with a minimum score of 7 were deemed to be of high quality. In our meta-analysis, fifteen articles had a performance score of more than $7^{2-4,16-27}$, and three studies scored 6 as medium quality²⁸⁻³⁰, as shown in Table. 2.

176

177 **3. 3. 1 Cardiovascular disease risk in long COVID-19 patients**

Compared to the control cohort, our meta-analysis showed a pooled OR of 1.87 (95% CI 1.56-2.25) ($I^2 = 99.4\%$, p= 0.000) for the overall risk of cardiovascular events, while major cardiovascular diseases (HR 1.52; 95% CI, 1.42-1.63; $I^2 = 69.1\%$, P= 0.021) and cardiovascular mortality (HR 1.65; 95% CI, 1.12-2.43; $I^2 = 39.7\%$, P= 0.173), indicating a higher risk among long COVID-19 patients (Supplementary material online, Appendix Figure. 1 A-C)

184

We noted a significant positive association between long COVID-19 and 17 185 cardiovascular disease outcomes, consisting of acute coronary disease (RR 1.44; 95% 186 CI, 1.21-1.70; $I^2 = 87.8\%$, P= 0.000) (Supplementary material online, Appendix 187 Figure. 2), angina (RR 1.33; 95% CI, 1.17-1.52; $I^2 = 80.4\%$, P= 0. 000) 188 (Supplementary material online, Appendix Figure. 3A), arrhythmia (RR 1.99; 95%) 189 CI, 1.44-2.74; $I^2 = 98.3\%$, P= 0.000) (Supplementary material online, Appendix 190 Figure. 4A), atrial fibrillation (OR 1.48; 95% CI, 1.25-1.75; $I^2 = 93.3\%$, P= 0.000) 191 (Supplementary material online, Appendix Figure. 5A), atrial flutter (RR 1.31; 95% 192 CI, 0.97-1.76; $I^2 = 92.2\%$, P= 0.000) (Supplementary material online, Appendix 193 Figure. 6), bradycardia (OR 1.48; 95% CI, 1.34-1.64; $I^2 = 88.2\%$, P= 0.000) 194 (Supplementary material online, Appendix Figure. 7), cardiac arrest (RR 1.95; 95% 195 CI, 1.48-2.58; $I^2 = 63.4\%$, P= 0.018) (Supplementary material online, Appendix 196 Figure. 8), cardiogenic shock (RR 1.85; 95% CI, 1.59-2.14; $I^2 = 0.0\%$, P= 0.604) 197 (Supplementary material online, Appendix Figure. 9), cardiomyopathy (RR 1.52; 95% 198

199	CI, 1.25-1.83; $I^2 = 93.4\%$, P= 0.000) (Supplementary material online, Appendix
200	Figure. 10A), coronary disease(HR 1.65; 95% CI, 1.28-2.14; I ² = 81.7%, P= 0.004)
201	(Supplementary material online, Appendix Figure. 11), heart failure (OR 1.77; 95%
202	CI, 1.52-2.05; $I^2 = 96.4\%$, P= 0.000) (Supplementary material online, Appendix
203	Figure. 12A), hypertension (HR 2.39; 95% CI, 0.60-9.62; $I^2 = 99.6\%$, P= 0.000)
204	(Supplementary material online, Appendix Figure. 13), ischemic heart disease (HR
205	1.49; 95% CI, 1.13-1.96; $I^2 = 97.3\%$, P= 0.000) (Supplementary material online,
206	Appendix Figure. 14), myocardial infarction (OR 1.63; 95% CI, 1.42-1.86; $I^2 = 80.9\%$,
207	P= 0.000) (Supplementary material online, Appendix Figure. 15), myocarditis (OR
208	4.42; 95% CI, 2.94-6.67; $I^2 = 69.7\%$, P= 0.000) (Supplementary material online,
209	Appendix Figure. 16), pericarditis (OR 2.07; 95% CI, 1.59-2.69; I ² = 85.9%, P= 0.000)
210	(Supplementary material online, Appendix Figure. 17) and tachycardia (OR 1.76; 95%
211	CI, 1.63-1.90; $I^2 = 82.8\%$, P= 0.000) (Supplementary material online, Appendix
212	Figure. 18).

213

Long COVID-19 patients had a higher risk of developing cardiovascular disease risk in relevant studies generally, according to the combined multivariate RR of 19 outcomes. A forest plot of the OR is shown in Figure. 2. We noted a significant positive association between long COVID-19 and 19 cardiovascular disease outcomes (RR 1.68; 95% CI, 1.55-1.81; $I^2 = 69.1\%$, P= 0.000).

219

220 The combined univariable OR of 4 outcomes was as well carried out, heart failure

221 (OR 1.56; 95% CI, 0.66-3.73; $I^2 = 97.6\%$, P= 0.000), myocarditis (OR 2.72; 95% CI, 222 0.40-18.32; $I^2 = 95.1\%$, P= 0.000), myocardial infarction (OR 2.37; 95% CI, 223 0.74-7.61; $I^2 = 77.5\%$, P= 0.035), pericarditis (OR 1.47; 95% CI, 0.29-7.42; $I^2 = 94$. 224 9%, P= 0.000), suggesting that confounding factors are prevalent, potentially 225 compromising the reliability of the results in univariate analysis, as shown in Figure. 226 3. However, the significance of aggregated analysis persists (OR 1.97; 95% CI, 227 1.11-3.52; $I^2 = 95.5\%$, P= 0.000).

228

229 **3. 3. 2 Subgroup Analysis**

A subgroup analysis was performed according to type of inpatient and outpatient, for 230 inpatient: angina (RR 1.70; 95% CI, 0.97-2.99; $I^2 = 87.9\%$, P= 0.004) and heart 231 failure (RR 1.47; 95% CI, 1.21-1.79; $I^2 = 86.0\%$, P= 0.000), as shown in 232 Supplementary material online, Appendix Figure. 3B and 12B, respectively; for 233 outpatient atrial fibrillation and flutter (RR 1.11; 95% CI, 0.82-1.52; $I^2 = 87.4\%$, P= 234 0.005) and heart failure (RR 1.06; 95% CI, 0.95-1.17; $I^2 = 0.0\%$, P= 0.879), as shown 235 in Supplementary material online, Appendix Figure. 5B and 12B, respectively. 236 Judging from the outcomes, it showed that the risk of HF significantly increased in 237 the inpatient group, may reflect severe COVID-19 would increase the risk of 238 long-term HF to some extent. Furthermore, there were 2 main subgroups for the 239 pathological type of cardiomyopathy, the subgroup analysis of ischemic 240 cardiomyopathy (RR 1.58; 95% CI, 1.11-2.26; $I^2 = 92.7\%$, P= 0.000) and 241 non-ischemic cardiomyopathy (RR 1.34; 95% CI, 1.10-1.64; $I^2 = 78.8\%$, P= 0.000), 242

as shown in Supplementary material online, Appendix Figure. 10B.

244

Meanwhile, there were also two other subgroup analyses, comprising ventricular arrhythmias (RR 1.70; 95% CI, 1.36-2.13; $I^2 = 84.9\%$, P= 0.000) and atrial fibrillation and flutter (RR 1.78; 95% CI, 0.97-3.25; $I^2 = 98.5\%$, P= 0.000), as shown in Supplementary material online, Appendix Figure. 4B and 5C.

249

Considering the limitation of retrospective cohort study, we also conducted the risk of 250 cardiovascular outcomes only based on prospective cohort studies, which is more 251 reliable. It displayed that atrial fibrillation (HR 1.60; 95% CI, 0.87-2.95; $I^2 = 94.6\%$. 252 P= 0.000), heart failure (HR 1.74; 95% CI, 1.25-2.41; $I^2 = 65.9\%$, P= 0.053), 253 pericarditis (HR 4.47; 95% CI, 3.15-6.35; $I^2 = 0.0\%$, P= 0.996), as shown in 254 Supplementary material online, Appendix Figure. 19. Also Pooled analysis 255 demonstrates the significance of the aforementioned three outcomes (HR 2.14; 95% 256 CI, 1.52-3.01; $I^2 = 89.6\%$, P = 0.000). 257

258

259 **3. 4. Heterogeneity and publication bias**

The heterogeneity was relatively high, but with the help of Meta-regression, we 260 figured out that country, study design, total number of samples, age at baseline and 261 total follow-up months of should be responsible for 262 sources of heterogeneity to a certain extent Supplementary material online, Appendix 263 Figure. 20-39). Meanwhile, owing to the observational research's character, all studies 264

265	inherently entail an inevitable risk of bias, irrespective of their quality rating ³¹ . The
266	results of the funnel plot, Begg's, and Egger's tests collectively indicated the absence
267	of publication bias in the meta-analysis basically (Supplementary material online,
268	Appendix Figure. 40, Supplementary material online, Appendix Table. 2-19).
269	
270	3. 5. Sensitivity analysis
271	Regarding the results displayed above, there was no discernible alteration in the
272	stability of the meta-analysis (Supplementary material online, Appendix Figure. 41).
273	
274	4. Discussion
275	At present, a definitive mechanism explaining the pathophysiology of long-COVID

276 contributing to cardiovascular diseases remains not conclusive. One hypothesis proposes that myocardial injury in COVID-19 may arise from either direct viral 277 invasion of cardiomyocytes or the presence of circulating inflammatory mediators, 278 including cytokines and/or endotoxins, or potentially a combination of both factors³². 279 Upon infection, there was an observed upregulation of ACE2, the receptor for 280 SARS-CoV-2, in the pulmonary alveolar epithelial barrier, vascular endothelial cells, 281 and cardiomyocytes³³. In single-nuclei RNA sequencing studies, robust expression of 282 ACE2 in the heart is evident in pericytes, vascular smooth muscle cells, fibroblasts, 283 and cardiomyocytes³⁴. An alternative hypothesis suggests that both hypo- and 284 hyper-immune responses may play a role in the severity of COVID-19, potentially 285 leading to systemic inflammatory responses or a cytokine storm, culminating in cell 286

death and multi-organ dysfunction³⁵. According to cell and animal models of SARS-CoV-2 infection, coupled with transcriptional and serum profiling of individuals with COVID-19, one experiment revealed a consistent and distinctive inflammatory reaction, whose response was characterized by reduced levels of type I and III interferons concomitant with elevated chemokine levels and prominent expression of Interleukin- 6 (IL-6)³⁶.

293

Numerous cohort studies have identified an association between long-term 294 COVID-19 and diverse cardiovascular outcomes. However, a comprehensive 295 systematic meta-analysis assessing composite cardiac outcomes is currently lacking. 296 This study employed meta-analysis techniques to evaluate the relationship between 297 298 long COVID-19 and cardiovascular outcomes. Our meta-analysis, based on the scrutiny of 18 articles comprising both retrospective and prospective studies, 299 encompassing 46, 083, 975 participants, revealed that individuals with long 300 COVID-19 face an increased risk of developing cardiovascular diseases overall. 301 Although the relatively high heterogeneity is acknowledged, it is inevitable for the 302 diversity arising from variations in countries, study designs, total sample sizes, 303 baseline ages, and durations of follow-up, as revealed by the results of 304 meta-regression. Additionally, the complexity of confounding factors presents a 305 challenge in achieving complete standardization. All included studies, even those with 306 a high rating, inherently entail an unavoidable risk of bias, owing to their 307 observational characteristic³¹. And we also hope to collect the data of long Covid 308

patients' BMI³⁷, smoking status³⁸⁻⁴⁰, diabetes⁴¹, high cholesterol^{42,43}, vaccination⁴⁴⁻⁴⁶
etc as much as possible, further identifying sources of heterogeneity. But in our study,
all the HRs, RRs and ORs are all over >1.0, as well as the absence of publication bias
based on the results of the funnel plot, Begg's, and Egger's tests, suggesting the model
is robust and reliable.

314

Hence, we propose that routine assessment of cardiac function is imperative for the 315 population with long COVID-19 who are at a heightened risk of cardiovascular 316 317 disease. Timely interventions have the potential to mitigate the risk of cardiovascular diseases and associated mortality. At present, the management of long COVID and 318 CV sequelae encompass a range of therapeutic interventions⁵: these interventions 319 320 comprise various rehabilitation programs, both through telemedicine and in-person consultations, targeting the amelioration of symptoms such as fatigue, cognitive 321 decline, and breathlessness; additionally, immunomodulatory treatments, including 322 steroids, laranilubmab, tocilizumab, atorvastatin, and colchicine, are also under 323 scrutiny; meanwhile, antifibrotic agents, like pirfenidone and LYT-100, as well as 324 anticoagulation strategies employing apixaban, are being experimented; furthermore, 325 there are therapies directed towards cognition enhancement, such as transcranial 326 stimulation, as well as metabolic modulators like niagen. What's more, Paxlovid 327 demonstrates higher efficacy in those harboring preexisting neurological or 328 cardiovascular conditions, individuals with immunosuppression and older patients⁴⁷. 329 But, the preeminent strategy for averting severe complications stemming from 330

SARS-CoV-2 infection is still vaccination^{48,49}. Furthermore, vigilant monitoring of
 viral infection-associated cardiac injury remains imperative throughout the
 management of COVID-19.

334

335 5. Limitations

We acknowledge certain limitations in our study that warrant consideration. Firstly, 336 several of our conducted meta-analyses displayed notable statistical heterogeneity, 337 which may potentially lead to an overestimation of the strength of associations, as 338 339 suggested by large meta-epidemiologic studies. The observed heterogeneity may be attributed to adjusted confounding factors and other variables within the included 340 studies. Additionally, among the 18 articles analyzed, special attention should be 341 342 given to the cumulative duration of follow-up, given the chronic nature of SARS-CoV-2 infection. Furthermore, retrospective cohort studies inherently introduce 343 a risk of bias. Therefore, there is an ongoing need for additional relevant cohort 344 345 studies, particularly prospective cohort studies, to enable a more comprehensive analysis. But it is crucial to emphasize that all studies included in our analysis 346 provided risk factors through multivariable regression, ensuring the derivation of 347 robust conclusions. 348

349

350 **6. Conclusions**

In summary, our study furnishes evidence indicating that individuals long COVID-19face a markedly elevated risk of developing cardiovascular outcomes. Implementing

353	intensified vaccination strategies, particularly with the latest COVID-19 vaccine, in
354	populations at a severe risk, and regularly monitoring cardiac function in those at a
355	high cardiovascular risk, may prove beneficial in mitigating the risk of cardiovascular
356	diseases and associated mortality in individuals with long COVID-19.
357	
358	Author Contributions
359	Study design: ZC, YH; Data collection: YH, ZW, HL, YL; Data analyses: YH, ZC;
360	Results visualization: YH; Results interpretations: YH, ZC; Manuscript writing: YH,
361	ZC; Manuscript revising: YH, ZW, HL, YL ZC. All authors approved the final version
362	of the manuscript.
363	
364	Funding
365	Special fund project for clinical research of Qingyuan People's Hospital
366	(QYRYCRC2023006), plan on enhancing scientific research in GMU
367	(GZMU-SH-301).
368	
369	
	Data Availability:
370	Data Availability : The research contributions presented in this article are detailed in the
370 371	
	The research contributions presented in this article are detailed in the
371	The research contributions presented in this article are detailed in the article/supplementary material; you can contact the relevant author for further

Declarations

Competing interests The authors declare that they have no competing interests. 375

376

Reference 377

- World Health Organization. Weekly operational update on COVID-19-4 July 2021. Weekly 378 1. 379 operational update on COVID-19 - 4 October 2023 (who.int)
- 380 2. Whittaker HR, Gulea C, Koteci A, Kallis C, Morgan AD, Iwundu C, Weeks M, Gupta R, Quint JK. 381 GP consultation rates for sequelae after acute covid-19 in patients managed in the 382 community or hospital in the UK: population based study. BMJ. 2021;375:e065834. doi: 383 10.1136/bmj-2021-065834
- 384 3. Wan EYF, Mathur S, Zhang R, Yan VKC, Lai FTT, Chui CSL, Li X, Wong CKH, Chan EWY, Yiu KH, et 385 al. Association of COVID-19 with short- and long-term risk of cardiovascular disease and 386 mortality: a prospective cohort in UK Biobank. Cardiovasc Res. 2023;119:1718-1727. doi: 387 10.1093/cvr/cvac195
- 388 4. Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 389 2023;29:2347-2357. doi: 10.1038/s41591-023-02521-2
- 390 Raman B, Bluemke DA, Luscher TF, Neubauer S. Long COVID: post-acute sequelae of 5. 391 COVID-19 with a cardiovascular focus. Eur Heart J. 2022;43:1157-1172. doi: 392 10.1093/eurheartj/ehac031
- Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9:129. doi: 393 6. 394 10.1016/S2213-2600(21)00031-X
- 395 7. Fernandez-de-Las-Penas C. Long COVID: current definition. Infection. 2022;50:285-286. doi: 396 10.1007/s15010-021-01696-5
- 397 Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, Lifelines Corona Research I. 8. 398 Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort 399 study. Lancet. 2022;400:452-461. doi: 10.1016/S0140-6736(22)01214-4
- 400 9. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and 401 recommendations. Nat Rev Microbiol. 2023;21:133-146. doi: 10.1038/s41579-022-00846-2
- 402 Healey Q, Sheikh A, Daines L, Vasileiou E. Symptoms and signs of long COVID: A rapid review 10. 403 and meta-analysis. J Glob Health. 2022;12:05014. doi: 10.7189/jogh.12.05014
- 404 11. Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, et al. SARS-CoV-2 infection 405 of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 406 2020;73:807-816. doi: 10.1016/j.jhep.2020.05.002
- 407 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of 12. 408 patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. 409 doi: 10.1016/S0140-6736(20)30183-5
- 410 Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 13. 411 2020;17:259-260. doi: 10.1038/s41569-020-0360-5
- 412 14. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends 413 Pharmacol Sci. 2004;25:291-294. doi: 10.1016/j.tips.2004.04.001
- 414 15. Sidik SM. Heart-disease risk soars after COVID - even with a mild case. Nature. 2022;602:560. 415 doi: 10.1038/d41586-022-00403-0

116	16	Wang W. Wang CV. Wang SL. Wei JC. Long term cardiovaccular outcomes in COVID 10
416	16.	Wang W, Wang CY, Wang SI, Wei JC. Long-term cardiovascular outcomes in COVID-19
417		survivors among non-vaccinated population: A retrospective cohort study from the TriNetX
418		US collaborative networks. <i>EClinicalMedicine</i> . 2022;53:101619. doi:
419		10.1016/j.eclinm.2022.101619
420	17.	Hong K, Kisiju T, Kim J, Chun BC. Cardio-cerebrovascular complications in COVID-19 patients:
421		A retrospective cohort study. Front Med (Lausanne). 2022;9:1045274. doi:
422		10.3389/fmed.2022.1045274
423	18.	Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med.
424		2022;28:583-590. doi: 10.1038/s41591-022-01689-3
425	19.	Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection.
426		Nat Med. 2022;28:2398-2405. doi: 10.1038/s41591-022-02051-3
427	20.	Lip GYH, Genaidy A, Tran G, Marroquin P, Estes C. Incident atrial fibrillation and its risk
428		prediction in patients developing COVID-19: A machine learning based algorithm approach.
429		Eur J Intern Med. 2021;91:53-58. doi: 10.1016/j.ejim.2021.04.023
430	21.	Salah HM, Fudim M, O'Neil ST, Manna A, Chute CG, Caughey MC. Post-recovery COVID-19 and
431		incident heart failure in the National COVID Cohort Collaborative (N3C) study. Nat Commun.
432		2022;13:4117. doi: 10.1038/s41467-022-31834-y
433	22.	Lam ICH, Wong CKH, Zhang R, Chui CSL, Lai FTT, Li X, Chan EWY, Luo H, Zhang Q, Man KKC, et
434		al. Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database
435		cohort study in Hong Kong and the UK. EClinicalMedicine. 2023;60:102000. doi:
436		10.1016/j.eclinm.2023.102000
437	23.	Ortega-Paz L, Arevalos V, Fernandez-Rodriguez D, Jimenez-Diaz V, Baneras J, Campo G,
438		Rodriguez-Santamarta M, Diaz JF, Scardino C, Gomez-Alvarez Z, et al. One-year cardiovascular
439		outcomes after coronavirus disease 2019: The cardiovascular COVID-19 registry. PLoS One.
440		2022;17:e0279333. doi: 10.1371/journal.pone.0279333
441	24.	Tuvali O, Tshori S, Derazne E, Hannuna RR, Afek A, Haberman D, Sella G, George J. The
442		Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients-A Large
443		Population-Based Study. J Clin Med. 2022;11. doi: 10.3390/jcm11082219
444	25.	Mabila S, Patel D, Fan M, Stahlman S, Seliga N, Nowak G, Wells N. Post -acute sequalae of
445	201	COVID-19 and cardiac outcomes in U. S. military members. Int J Cardiol Cardiovasc Risk Prev.
446		2023;17:200183. doi: 10.1016/j.ijcrp.2023.200183
447	26.	Raisi-Estabragh Z, Cooper J, Salih A, Raman B, Lee AM, Neubauer S, Harvey NC, Petersen SE.
448	20.	Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank. <i>Heart</i> .
449		2022;109:119-126. doi: 10.1136/heartjnl-2022-321492
450	27.	Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19.
450 451	27.	Nature. 2021;594:259-264. doi: 10.1038/s41586-021-03553-9
	20	
452	28.	Katsoularis I, Fonseca-Rodriguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute
453		myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled
454		case series and matched cohort study. <i>Lancet</i> . 2021;398:599-607. doi:
455		10.1016/S0140-6736(21)00896-5
456	29.	Cohen K, Ren S, Heath K, Dasmarinas MC, Jubilo KG, Guo Y, Lipsitch M, Daugherty SE. Risk of
457		persistent and new clinical sequelae among adults aged 65 years and older during the
458		post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ.
459		2022;376:e068414. doi: 10.1136/bmj-2021-068414

medRxiv preprint doi: https://doi.org/10.1101/2023.12.30.23300656; this version posted December 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 30. Zhang HG, Dagliati A, Shakeri Hossein Abad Z, Xiong X, Bonzel CL, Xia Z, Tan BWQ, Avillach P,
 Brat GA, Hong C, et al. International electronic health record-derived post-acute sequelae
 profiles of COVID-19 patients. *NPJ Digit Med*. 2022;5:81. doi: 10.1038/s41746-022-00623-8
- 463 31. Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, Clark A, Ntatsaki E,
- 464 Vassiliou VS. Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and
- 465 Meta-analysis. JAMA Intern Med. 2023;183:566-580. doi: 10.1001/jamainternmed.2023.0750
- Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, Cao S, Liu X, Xiang Y, Zhao Q, et al. Characteristics and
 clinical significance of myocardial injury in patients with severe coronavirus disease 2019. *Eur Heart J.* 2020;41:2070-2079. doi: 10.1093/eurheartj/ehaa408
- Ma S, Sun S, Li J, Fan Y, Qu J, Sun L, Wang S, Zhang Y, Yang S, Liu Z, et al. Single-cell
 transcriptomic atlas of primate cardiopulmonary aging. *Cell Res.* 2021;31:415-432. doi:
 10.1038/s41422-020-00412-6
- 472 34. Tucker NR, Chaffin M, Bedi KC, Jr., Papangeli I, Akkad AD, Arduini A, Hayat S, Eraslan G, Muus
 473 C, Bhattacharyya RP, et al. Myocyte-Specific Upregulation of ACE2 in Cardiovascular Disease:
 474 Implications for SARS-CoV-2-Mediated Myocarditis. *Circulation*. 2020;142:708-710. doi:
 475 10.1161/CIRCULATIONAHA.120.047911
- 476 35. Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV, 3rd, Kwon DH, Singh T,
 477 Tilton JC, Tsai EJ, et al. COVID-19 and Cardiovascular Disease: From Bench to Bedside. *Circ Res.*478 2021;128:1214-1236. doi: 10.1161/CIRCRESAHA.121.317997
- 479 36. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, Jordan TX, Oishi K,
 480 Panis M, Sachs D, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of
 481 COVID-19. *Cell*. 2020;181:1036-1045 e1039. doi: 10.1016/j.cell.2020.04.026
- 482 37. Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele
 483 CE, Neeland IJ, Sanders P, et al. Obesity and Cardiovascular Disease: A Scientific Statement
 484 From the American Heart Association. *Circulation*. 2021;143:e984-e1010. doi:
 485 10.1161/CIR.00000000000973
- 486 38. Duncan MS, Greevy RA, Tindle HA, Vasan RS, Lipworth L, Aldrich MC, Lloyd-Jones DM,
 487 Freiberg MS. Inclusion of Smoking Data in Cardiovascular Disease Risk Estimation. JAMA
 488 Cardiol. 2022;7:195-203. doi: 10.1001/jamacardio.2021.4990
- 489 39. Duncan MS, Freiberg MS, Greevy RA, Jr., Kundu S, Vasan RS, Tindle HA. Association of
 490 Smoking Cessation With Subsequent Risk of Cardiovascular Disease. *JAMA*. 2019;322:642-650.
 491 doi: 10.1001/jama.2019.10298
- 492 40. Leigh A, McEvoy JW, Garg P, Carr JJ, Sandfort V, Oelsner EC, Budoff M, Herrington D, Yeboah J.
 493 Coronary Artery Calcium Scores and Atherosclerotic Cardiovascular Disease Risk Stratification
 494 in Smokers. *JACC Cardiovasc Imaging*. 2019;12:852-861. doi: 10.1016/j.jcmg.2017.12.017
- 495 41. Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, Di Palo KE, Golden SH, 496 Sperling LS, American Heart Association Diabetes Committee of the Council on L, et al. 497 Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: 498 Scientific Statement From the American Heart Association. Circulation. А 499 2022;145:e722-e759. doi: 10.1161/CIR.0000000000001040
- 500 42. Doi T, Langsted A, Nordestgaard BG. Elevated Remnant Cholesterol Reclassifies Risk of
 501 Ischemic Heart Disease and Myocardial Infarction. J Am Coll Cardiol. 2022;79:2383-2397. doi:
 502 10.1016/j.jacc.2022.03.384
- 503 43. Trinder M, Francis GA, Brunham LR. Association of Monogenic vs Polygenic

504		Unaverse electron lensing With Diele of Athonocalemetic Condinuscentler Discose (AAAA Condial
504		Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. JAMA Cardiol.
505		2020;5:390-399. doi: 10.1001/jamacardio.2019.5954
506	44.	Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti
507		K, Harnden A, Coupland CAC, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias
508		associated with COVID-19 vaccination or SARS-CoV-2 infection. <i>Nat Med.</i> 2022;28:410-422.
509		doi: 10.1038/s41591-021-01630-0
510	45.	Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti
511		K, Harnden A, Coupland CAC, et al. Risk of Myocarditis After Sequential Doses of COVID-19
512		Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation. 2022;146:743-754. doi:
513		10.1161/CIRCULATIONAHA.122.059970
514	46.	Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, Donahue JG, Kharbanda EO,
515		Naleway A, Nelson JC, et al. Surveillance for Adverse Events After COVID-19 mRNA
516		Vaccination. JAMA. 2021;326:1390-1399. doi: 10.1001/jama.2021.15072
517	47.	Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein LH, Saliba W.
518		Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in
519		High-Risk Patients. Clin Infect Dis. 2023;76:e342-e349. doi: 10.1093/cid/ciac443
520	48.	Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C,
521		Fennema H, Spiessens B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine
522		against Covid-19. N Engl J Med. 2021;384:2187-2201. doi: 10.1056/NEJMoa2101544
523	49.	Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G,
524		Pan K, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2
525		infections and COVID-19 cases, hospitalisations, and deaths following a nationwide
526		vaccination campaign in Israel: an observational study using national surveillance data.
527		Lancet. 2021;397:1819-1829. doi: 10.1016/S0140-6736(21)00947-8
528		
	T .	
529	Figure	legends
520		
530		
524	F :	1 Flow discourse outlining the general stude and study identification for
531	rigure	1. Flow diagram outlining the search strategy and study identification for
522	moto c	malvaia
532	meta-a	nalysis.
533		
534	T !	
534	Figure	2. A meta-analysis of the combined multivariate relative risk of 19
535	outcon	nes.
536		
	Б,	
537	Figure	3. A meta-analysis of the combined univariable the combined OR of 4

538 outcomes.

Table 1. Characteristics of the included studies in the meta-analysis.


							Total length of follow up		COVID Sample	-19 (COVID-19 Samj)	BMI(kį	g/ <i>M</i> ²)				Smokinį	g, %					Diab	bete, %					High cl	nolestero	l, %				V	⁷ accinati	ion, %		
Study	Country	Race	Study design	Total number of samples	Male %	Age at baseline	(months)						N CO 1	O VID- 9	COVII 19)-	No CC	OVID-19)	C	OVID-1	19	No	COVID	-19		COVI	D-19		No COV	TD-19		COVI	D-19		No CC	OVID-19	9	C(OVID-19)
																	Yes	N	0	Yes		No	Yes		No	Y	es	No	Ŋ	es	No	Y	es	No		Yes	N	lo	Yes	ľ	No
								Tot al	Male	Fem ale	Tot Ma al e	l Fem ale	n Me an	SD	Me an	S D Sar plo	n %	Sam ple	%	Sa mpl % e	Sa % mj e	a pl %	Sam ple	% Sa % pl	m %	Sam ple	%	Sam o ple	Sam % ple	%	Sam 9/ ple	Sa 6 mpl e	%	Sa mpl % e	Sa % pl	m % le	Sam ple	%	Sa mpl % e	6 Sam 9 ple	^l %
Benjamin Bowe 2022 ¹⁹	America	Mixe d	retrospecti ve cohort study	928,123	89.85	63.20 (16.53)	12	443, 588	386,8 97	56,6 91	484, 423 535 100	, 61,4) 35	29.9 3	5.3 3	31.0 d	5.0 5.0 6 8	7 53. 1 84	2,46 0,91 1	46. 1 13	264, 5 344 5	56 19	0, 45. 91 44	1,33 1,01 5	24. 4,0 95 4	00 75. 05	156, 173	32. 23	328, 6 362 7	7. NA 7	N A	NA A	NA	N A	NA I	2,(N 2,(A {	07 38. 00 84	3,26 2,71 9	61. 16	173, 3: 187 7	5. 311, 4 347	64. 26
Benjamin Bowe 2023 ⁴	America	Mixe d	retrospecti ve cohort study	6,124,045	90.00	62.84(16.27)	24	5,98 5,22 7	5,387 ,901	597, 326	138, 123 818 687	, 15,1 7 31	30.2	5.7	30.3	5.7 5.7 5 5 5 5	0 56. 8 97	2,57 5,54 2	43. 03	79,1 5 40 0	7. 59,)1 78	,6 42. 8 99	1,71 6,56 3	28. 4,2 68 8,6 4	26 56 71. 32	40,4 38	29. 13	98,3 7 80 8	0. NA 7	N A	NA A	NA	N A	NA .	N N. A	A A	NA	N A	NA /	J NA	N A
Eric Yuk Fai Wan 2023 ³	China	NA	prospectiv e cohort study	149,749	48.08	65.85 (8.26)	18	142, 610	68,52 4	74,0 86	7,13 3,47 9 6	7 3,66 3	27.3	4.8	27.4	4.5 955	13. 38	6,18 4	86. 62	18,6 1 22 0	3. 123 06 98	3, 86. 8 94	NA	N NA	A N A	NA	N A	NA	N NA	N A	NA A	NA NA	N A	NA	N N. A	A N A	NA	N A	NA /	NA NA	N A
Gregory Y.H. Lip 2021 ²⁰	Britain	NA	prospectiv e cohort study retrospecti	280,592	41.2	72.5 (9.9)	32	NA	NA	NA	NA NA	. NA	NA	N A	NA	N NA A	N A	NA	N A	NA Z	N NA	A NA	NA	N NA	A N A	NA	N A	NA Z	N NA	N A	NA A	NA NA	N A	NA	N N A	A A	NA	N A	NA /	I NA	N A
Hannah R Whittaker 2021 ²	Britain	NA	ve cohort study	494,513	44.32	44.38(16.79)	9.2	38,5 11	15,42 3	23,0 88	456, 203 002 723	, 252, 279	NA	N A	NA	N NA A	N A	NA	N A	NA	N NA A	A NA	NA	N A	A N A	NA	N A	NA 2	N NA	N A	NA A	NA	N A	NA	N N. A	A N A	NA	N A	NA A	NA	N A
Harrison G. Zhang 2022 ³⁰	America	NA	retrospecti ve cohort study	2,745,130	63.16	53.62 (18.10)	14 ecember 31, 20	2,33 0,52 8	1,460 ,871	869, 4 657	414, 272 602 868 this	, 141, 8 734	NA	N A	NA	N A	N A	NA	N A	NA /	N A	A NA	NA	N A	A N A	NA	N A	NA	N NA	N A	NA A	NA	N A	NA	N A	A A	NA	N A	NA /	J NA	N A
Husam M. Salah	America	s not certil Mixe	ied by peer re retrospecti It is made ava	view) is the a	uthor/funde perpetuity CC4526NC	22.70)	ional license .	257,	display the 125,6	131,	in 330, 140	, 190,	NA	N	NA	N NA	N	NA	N	NA	N N/	A NA	54,3	16. 27	5, 83.	60,6	23.	196, 7	6. NA	N	NA	J NA	N	NA	NN	N	NA	N	۲ NA	۱ NA	Ν
2022 ²¹		d	study			(22.70)		075	84	391	255 147	108		A		A	A		A	1	A		71	46 88	4 54	82	60	393 4	0	А	A	A	А	1	A	A		А	A	1	А
Ioannis Katsoularis 2021 ²⁸	Sweden	NA	retrospecti ve cohort study	435,223	NA	NA					86,7 37 42 235																														
Ivan Chun Hang Lam 2023 ²²	China	NA	retrospecti ve cohort study	8,516,716	44.15	55.49(17.61)	28	4,26 0,01 5	1,877 ,970	2,38 2,04 5	4,25 1,88 5,70 1,76 1 1	3 2,37 5 4,94 0	NA	N A	NA	N NA A	N A	NA	N A	NA Z	N NA	A NA	488, 876	3,7 11. 1,1 48 9	88. 3 52	539, 760	12. 68	3,71 6,94 1 3	7. NA 2	N A	NA A	NA	N A	NA ,	N 94 A 18	2, 22. 36 12	3,31 7,82 9	77. 88	941, 22 678 1	2. 3,31 2. 5,02 2 3	77. 88
Ken Cohen 2021 ²⁹	America	Mixe d	retrospecti ve cohort study	5,652,190	42.30	73.85 (4.50)	24	5,51 8,82 4	2,332 ,984	3,18 5,84 0	133, 58,1 366 10	1 75,2 56	NA	N A	NA	N 304 A 507	, 5.5 7 2	5,21 4,31 7	94 1 48	5,87 4 8	.4 12 [°] 1 48	7, 95. 8 59	54,5 58	40. 78 91 08	,8 59. 3 09	1,69 1,13 1	30. 64	3,82 7,69 3	9. NA 6	N A	NA A	NA	N A	NA .	N N. A	A A	NA	N A	NA 4	NA	N A
Kwan Hong 2022 ¹⁷	South Korea	NA	retrospecti ve cohort study	2,30,327	47.46	NA	5	2,22 ,257	106,0 82	116, 175	8,07 3,23 0 6	3 4,83 4	NA	N A	NA	N A	N A	NA	N A	NA /	N A	A NA	30,0 05	13. 19 5 25	2, 86. 2 5	1,16 2	14. 4	6,90 8 8 9	5. 21,3 5 37	9.6	200, 90 920 4). 815	10. 1	7,25 8 5	9. 9 N	A A	NA	N A	NA /	J NA A	N A
Luis Ortega-Paz1 2022 ²³	Spain	NA	retrospecti ve cohort study	4,427	53.90	60.36(18.53)	12	849	354	495	3,57 2,03 8 2	3 1,54 6	26	5.0	28.4	5.3 283	33. 33	566	66. 67	958 2 7	26. 2,6 77 0	52 73. 23	63	7.4 2 78	6 92. 58	721	20. 15	2,85 7 7 8	9. NA 5	N A	NA A	NA	N A	NA .	N A 66	78. 54 21	185	21. 79	950 20 5	5. 2628 5	73. }
Ortal Tuvali 2022 ²⁴	Israel	Mixe d	retrospecti ve cohort study	787,968	45.72	42.4 (17.70)	6	590, 976	270,2 10	320, 766	196, 90,0 992 70) 106, 922	26.1	7.1	27.1	169 5.7 467	9, 28. 7 68	383, 002	64 81	38,7 1 41 6	9. 13 [°] 57 07'	7, 69. 19 59	61,9 78	10. 52 49 99	8, 89. 8 51	25,5 83	12. 99	171, 8 409 0	7. 183, 1 704	31. 08	407, 68 272 9	3. 60,6 2 29	30. 78	136, 6 363 2	9. N. 22 N.	A A	NA	N A	NA /	I NA	N A
Sithembile Mabila 2022 ²⁵			study			27.99 (7.96)					875, 701 361 090																														
Weijie Wang 2022 ¹⁶	China	Mixe d	ve cohort study	1,381,156	43.16	43.15(16.15)					590, 297 552 939																														
Yan Xie 2022 ¹⁸	America	Mixe d	retrospecti ve cohort study	11,650,81 8	90.26	63.38 (16.26)	12	11,4 97,0 58	10,37 7,853	1,11 9,20 5	153, 137 760 617	, 16,1 43	28.6 5	3.7 6	28.7 3 6	3.8 1 2,4 4	0 57. 7 43	4,89 4,70 0	42. 57	91,7 5 81 6	59. 61, 59 79	,9 40. 9 31	8,87 7,84 4	77. 9,2 22 4	51 22. 78	116, 256	75. 61	37,5 2 04 3	4. 9 1	74. 29	2,95 5,74 7 7	5. 111, 1 922	72. 79	41,8 2 38 2	7. N. 21 N.	A A	NA	N A	NA /	NA	N A
Zahra Raisi-Estabragh 2022 ²⁶	Britain	NA	prospectiv e cohort study	53,613	47.04	65(11.11)					17,8 8,40 71 9																														
Ziyad Al-Aly 2021 ²⁷	America	Mixe d	retrospecti ve cohort study	5,064,270	90.42	66.59(16.37)	6.8	4,99 0,83 5	4,514 ,365	476, 7 470	73,4 64,5 35 55	5 8,88 0	NA	N A	NA	N NA A	N A	NA	N A	NA Z	N NA	A NA	NA	N NA	A N A	NA	N A	NA	N NA A	N A	NA A	NA	N A	NA .	N N. A	A A	NA	N A	NA /	I NA	N A

#NA, not available.

Source	Selection	Comparability	Outcome	Total Score
Benjamin Bowe 2022 ¹⁹	+++	++	+++	8
Benjamin Bowe 2023 ⁴	++++	++	+++	9
Eric Yuk Fai Wan 2023 ³	+++	++	++	7
Gregory Y.H. Lip 2021 ²⁰	++++	++	++	8
Hannah R Whittaker 2021 ²	++++	++	++	8
Harrison G. Zhang 2022 ³⁰	+++	++	+	6
Husam M. Salah 2022 ²¹	+++	++	++	7
Ioannis Katsoularis 2021 ²⁸	+++	++	+	6
Ivan Chun Hang Lam 2023 ²²	++++	++	++	8
Ken Cohen 2021 ²⁹	+++	++	+	6
Kwan Hong 2022 ¹⁷	++++	++	+	7
Luis Ortega-Pazl 2022 ²³	++++	++	++	8
Ortal Tuvali 2022 ²⁴	++++	++	++	8
Sithembile Mabila 2022 ²⁵	+++	++	++	7
Weijie Wang 2022 ¹⁶	+++	++	++	7
Yan Xie 2022 ¹⁸	+++	++	++	7
Zahra Raisi-Estabragh 2022 ²⁶	++++	++	++	8
Ziyad Al-Aly 2021 ²⁷	++++	++	++	8

Table. 2 Quality assessment of the included studies in the meta-analysis.

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only



OutcomestudieAcute coronary disease6Angina9Arrhythmia10Atrial fibrillation9Atrial fibrillation5	 < 0.001 < 0.001 < 0.001 	12 87.7% 80.4% → :	OR (95% CI) 1.44 (1.21, 1.70)	Weigh 6.37
Angina 9 Arrhythmia 10 Atrial fibrillation 9	< 0.001		1.44 (1.21, 1.70)	6.37
Arrhythmia 10 Atrial fibrillation 9		80.4%		
Atrial fibrillation 9	< 0.001		1.33 (1.17, 1.52)	7.28
	< 0.001	98.3%	▲ 1.99 (1.44, 2.74)	3.57
A. 1. 1. 0. 11	< 0.001	93.3%	1.48 (1.25, 1.75)	6.41
Atrial flutter 5	< 0.001	92.2%	1.31 (0.97, 1.76)	3.91
Bradycardia 5	< 0.001	88.2%	1.48 (1.34, 1.64)	7.94
Cardiac arrest 6	0.018	63.4%	→ 1.95 (1.48, 2.58)	4.22
Cardiac Events 8	< 0.001	99.4%	1.87 (1.56, 2.25)	6.08
Cardiovascular mortality 4	0.173	39.7%	1.65 (1.12, 2.43)	2.80
Cardiogenic Shock 8	0.604	0.0%	- 1.85 (1.59, 2.14)	6.87
Cardiomyopathy 14	< 0.001	93.4%	1.52 (1.25, 1.83)	5.91
Coronary Disease 3	0.004	81.7%%	1.65 (1.28, 2.14)	4.58
Heart failure 13	< 0.001	96.4%	- 1.77 (1.52, 2.05)	6.84
Hypertension 4	< 0.001	99.6%	• 2.39 (0.60, 9.62)	0.30
Ischemic Heart Disease 4	< 0.001	97.3%	1.49 (1.13, 1.96)	4.26
Myocardial infarction 12	< 0.001	80.9%	1.63 (1.42, 1.86)	7.18
Myocarditis 10	< 0.001	69.7%	4.42 (2.94, 6.67)	2.59
Pericarditis 9	< 0.001	85.9%	◆ 2.07 (1.59, 2.69)	4.47
Tachycardia 7	< 0.001	82.8%	1.76 (1.63, 1.90)	8.42
Overall (I-squared = 69.1%, p =	= 0.000)		1.68 (1.55, 1.81)	100.

Study		%
ID	OR (95% CI)	Weight
Heart Failure		
Sithembile Mabila 2022	2.45 (1.95, 3.10)	13.72
Hannah R Whittaker 2021 🔶	1.01 (0.88, 1.15)	13.93
Subtotal (I-squared = 97.6%, p = 0.000)	1.56 (0.66, 3.73)	27.65
Myocarditis		
Ortal Tuvali 2022	1.00 (0.47, 2.13)	11.32
Sithembile Mabila 2022	7.00 (4.81, 10.20)	13.24
Subtotal (I-squared = 95.1%, p = 0.000)	2 .72 (0.40, 18.32)	24.56
Myocardial infarction		
Sithembile Mabila 2022	1.23 (0.48, 3.18)	10.20
Ioannis Katsoularis 2021	4.06 (2.27, 7.25)	12.29
Subtotal (I-squared = 77.5%, p = 0.035)	2.37 (0.74, 7.61)	22.49
Pericarditis		
Ortal Tuvali 2022	0.63 (0.33, 1.22)	11.89
Sithembile Mabila 2022	3.28 (2.35, 4.57)	13.41
Subtotal (I-squared = 94.9%, p = 0.000)	1.47 (0.29, 7.42)	25.30

T

1

1.97 (1.11, 3.52) 100.00

NOTE: Weights are from random effects analysis

Overall (I-squared = 95.5%, p = 0.000)

<mark>ا</mark> .0546 І 18.3

3.3